PMID- 23556071
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20130405
LR  - 20211021
IS  - 2040-6207 (Print)
IS  - 2040-6215 (Electronic)
IS  - 2040-6207 (Linking)
VI  - 2
IP  - 1
DP  - 2011 Feb
TI  - Long-Term Results of Fludarabine/Melphalan as a Reduced-Intensity Conditioning 
      Regimen in Mantle Cell Lymphoma: The GELTAMO Experience.
PG  - 5-10
LID - 10.1177/2040620710396752 [doi]
AB  - BACKGROUND: We herein report the long-term results of an allogeneic 
      reduced-intensity conditioning (allo-RIC) protocol used in 21 consecutive 
      patients (16 males, median age 56 years, 71% in complete remission) diagnosed 
      with mantle cell lymphoma (MCL). METHODS: The allo-RIC consisted of fludarabine 
      plus melphalan and peripheral blood hematopoietic stem cells (PBSCs) from human 
      leukocyte antigen (HLA)-identical siblings were used in all cases. Median CD34+ 
      infused cells was 5.8 times 10(6)/kg. All patients engrafted promptly. RESULTS: 
      Early toxicity included mild/moderate mucositis (43%), febrile neutropenia (33%) 
      and bacterial infections (19%). With a median follow up of 48 months, four deaths 
      were reported, all due to infections and/or graft-versus-host disease (GVHD), 
      yielding a 3-year cumulative incidence of nonrelapse mortality of 19.5%. Grade 
      III-IV acute GVHD occurred in 15% and chronic GVHD in 78%, being extensive in 
      39%. The 5-year progression-free survival (PFS) and overall survival (OS) were 
      both 80% (95% CI: 63-97%). Age was the only possible prognostic factor for OS, 
      which was 43% for those aged more than 60 years and 100% for those younger (p < 
      0.001). CONCLUSIONS: Our data confirm that allo-RIC offers a low toxicity profile 
      and a chance for prolonged long-term disease-free survival in MCL, particularly 
      in younger patients.
FAU - Cruz, Jorge Gayoso
AU  - Cruz JG
AD  - Servicio de Hematologia, Hospital Santa Creu i Sant Pau, Barcelona, Spain.
FAU - Martino, Rodrigo
AU  - Martino R
FAU - Balsalobre, Pascual
AU  - Balsalobre P
FAU - Heras, Inmaculada
AU  - Heras I
FAU - Pinana, Jose Luis
AU  - Pinana JL
FAU - Serrano, David
AU  - Serrano D
FAU - de la Serna, Javier
AU  - de la Serna J
FAU - Tomas, Jose Francisco
AU  - Tomas JF
FAU - Diez-Martiin, Josea Luis
AU  - Diez-Martiin JL
FAU - Caballero, Dolores
AU  - Caballero D
LA  - eng
PT  - Journal Article
PL  - England
TA  - Ther Adv Hematol
JT  - Therapeutic advances in hematology
JID - 101549589
PMC - PMC3573392
OTO - NOTNLM
OT  - allogeneic transplantation
OT  - mantle cell lymphoma
OT  - reduced intensity conditioning
COIS- The authors declare that there is no potential conflict of interest.
EDAT- 2011/02/01 00:00
MHDA- 2011/02/01 00:01
PMCR- 2011/02/01
CRDT- 2013/04/05 06:00
PHST- 2013/04/05 06:00 [entrez]
PHST- 2011/02/01 00:00 [pubmed]
PHST- 2011/02/01 00:01 [medline]
PHST- 2011/02/01 00:00 [pmc-release]
AID - 10.1177_2040620710396752 [pii]
AID - 10.1177/2040620710396752 [doi]
PST - ppublish
SO  - Ther Adv Hematol. 2011 Feb;2(1):5-10. doi: 10.1177/2040620710396752.